Basic Info

Website: http://www.syntapharma.com/
Stock symbol: SNTA
IPO date:2/6/07
Total shares outstanding:33.82M (5M offered at IPO)
Other reviews: Seeking Alpha

Drugs/Platforms

Drugs in trials:
STA-4783 starting Phase 3 trials for treatment of melastatic melanoma
STA-5326 in Phase 2 trials for the treatment of Rheumatoid Arthritus and CVID

Drugs in development:
STA-9090 a heat shock protein inhibitor for the treatment of cancer
STA-9584 a vascular disrupting agent for the treatment of cancer
CRAC Channel Inhibitor for potential treatment of graft-versus-host disease (GVHD), immune disorders, allergies, and asthma.

Financials

Income: Yeah right!
Cash on hand:62.9million (as of the end of 2005)
Burn Rate:68.9 million (for 2005)
These numbers are pre-IPO, we’ll get to the cash infusion from the IPO later.

Are their any numbers/info you’d like to see on this overview posts in the future?

Next up on babybiotechs.com: Syntana’s most promising drug, STA-4783.

Filed under: Synta Pharmaceuticals (SNTA)